Latest Development Pipeline News

The GPT Group delivered solid financial and operational results for 2025, growing assets under management to nearly $40 billion and advancing strategic partnerships across retail, logistics, and office sectors.

Aspen Group (ASX: APZ) has delivered robust operational and financial results for the nine months ending 31 March 2026, showing significant growth in rental income, development profits, and earnings. The company confirms it remains on track to meet its full-year guidance for FY26 and FY27 amid a supportive market environment.

NEXTDC Limited (ASX:NXT) has announced a A$1 billion wholesale offer of subordinated hybrid securities, fully backed by a binding commitment from Canadian investment group La Caisse. The capital raise aims to support NEXTDC’s growth strategy and infrastructure expansion through to FY29.

Summerset Group Holdings Limited reported a 34% increase in new occupation right sales in the first quarter of 2026 compared to the same period last year, alongside a 19% rise in resales. Despite rising fuel prices linked to geopolitical tensions, the company maintains a strong sales pipeline and cost management strategies.

Algorae Pharmaceuticals has launched a second collaboration with Peter MacCallum Cancer Centre to validate AI-predicted drug combinations across multiple cancer types, aiming to accelerate its drug development pipeline.

Infratil has upgraded its FY27 EBITDAF guidance for CDC Data Centres to A$680-720 million, citing accelerating construction and strong demand driven by AI and hyperscale cloud growth. The company also secured A$500 million equity funding and plans a bank debt upsizing to support expansion.

EVE Health Group has announced a $1.3 million capital raising through a placement of shares and free attaching options, aimed at advancing its pharmaceutical product rollout and development pipeline. Several components of the offer await shareholder approval at an upcoming general meeting.

Argenica Therapeutics has secured a nearly $4 million R&D tax incentive rebate for FY25, strengthening its cash position as it prepares for a pivotal Phase 2b trial of its neuroprotective peptide ARG-007.

Immutep Limited’s shares have resumed trading following the release of an interim futility analysis from its pivotal TACTI-004 Phase III trial of eftilagimod alfa.

Imugene Limited has launched a $20 million capital raising through a $12 million institutional placement and an $8 million Share Purchase Plan, alongside a convertible notes amendment to support its clinical development pipeline.

Island Pharmaceuticals has partnered with the Burnet Institute to explore new antiviral applications for its lead drugs, targeting measles, chikungunya, and Ross River virus. This collaboration leverages existing data and government funding to enhance the company’s clinical pipeline without major capital outlay.

Complii FinTech Solutions reported a $1.35 million loss for H1 FY26 alongside a 6% increase in annual recurring revenue, driven by strategic platform upgrades and expanding client engagement.